Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome
Authors
Lee, Rebecca JWysocki, O
Bhogal, T.
Shotton, R
Tivey, Ann
Angelakas, A.
Aung, T.
Banfill, K.
Baxter, M.
Boyce, H.
Brearton, G.
Copson, E.
Dickens, E.
Eastlake, L.
Gomes, F.
Hague, C.
Harrison, M.
Horsley, L.
Huddar, P.
Hudson, Z.
Khan, S.
Khan, U. T.
Maynard, A.
McKenzie, H.
Palmer, D.
Robinson, T.
Rowe, M.
Thomas, A.
Tweedy, J.
Sheehan, R.
Stockdale, A
Weaver, J.
Williams, S.
Wilson, C.
Zhou, C.
Dive, C.
Cooksley, Timothy J
Palmieri, C.
Freitas, A
Armstrong, Anne C
Affiliation
The Christie NHS Foundation Trust, Manchester, UK; The University of Manchester, Manchester, UK; Tumour Cell Biology Laboratory, The Francis Crick Institute, London, UK.Issue Date
2020
Metadata
Show full item recordAbstract
Background: Cancer patients are at increased risk of death from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Cancer and its treatment affect many haematological and biochemical parameters, therefore we analysed these prior to and during coronavirus disease 2019 (COVID-19) and correlated them with outcome. Patients and methods: Consecutive patients with cancer testing positive for SARS-CoV-2 in centres throughout the United Kingdom were identified and entered into a database following local governance approval. Clinical and longitudinal laboratory data were extracted from patient records. Data were analysed using Mann-Whitney U test, Fisher's exact test, Wilcoxon signed rank test, logistic regression, or linear regression for outcomes. Hierarchical clustering of heatmaps was performed using Ward's method. Results: In total, 302 patients were included in three cohorts: Manchester (n = 67), Liverpool (n = 62), and UK (n = 173). In the entire cohort (N = 302), median age was 69 (range 19-93 years), including 163 males and 139 females; of these, 216 were diagnosed with a solid tumour and 86 with a haematological cancer. Preinfection lymphopaenia, neutropaenia and lactate dehydrogenase (LDH) were not associated with oxygen requirement (O2) or death. Lymphocyte count (P < 0.001), platelet count (P = 0.03), LDH (P < 0.0001) and albumin (P < 0.0001) significantly changed from preinfection to during infection. High rather than low neutrophils at day 0 (P = 0.007), higher maximal neutrophils during COVID-19 (P = 0.026) and higher neutrophil-to-lymphocyte ratio (NLR; P = 0.01) were associated with death. In multivariable analysis, age (P = 0.002), haematological cancer (P = 0.034), C-reactive protein (P = 0.004), NLR (P = 0.036) and albumin (P = 0.02) at day 0 were significant predictors of death. In the Manchester/Liverpool cohort 30 patients have restarted therapy following COVID-19, with no additional complications requiring readmission. Conclusion: Preinfection biochemical/haematological parameters were not associated with worse outcome in cancer patients. Restarting treatment following COVID-19 was not associated with additional complications. Neutropaenia due to cancer/treatment is not associated with COVID-19 mortality. Cancer therapy, particularly in patients with solid tumours, need not be delayed or omitted due to concerns that treatment itself increases COVID-19 severity.Citation
Lee RJ, Wysocki O, Bhogal T, Shotton R, Tivey A, Angelakas A, et al. Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome. ESMO Open. 2020;6(1):100005.Journal
ESMO OpenDOI
10.1016/j.esmoop.2020.100005PubMed ID
33399072Additional Links
https://dx.doi.org/10.1016/j.esmoop.2020.100005Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.esmoop.2020.100005
Scopus Count
Collections
Related articles
- Haematological Parameters And Outcome In Hospitalized Patients With Covid-19: A Developing Country Experience.
- Authors: Iftikhar R, Kamran SM, Mirza ZE, Naseem A, Ali Shah SA, Riaz S, Fazal I, Alamgir W, Saeed F, Saleem S, Ali RS, Chaudhry QUN
- Issue date: 2021 Jul-Sep
- Routine laboratory testing to determine if a patient has COVID-19.
- Authors: Stegeman I, Ochodo EA, Guleid F, Holtman GA, Yang B, Davenport C, Deeks JJ, Dinnes J, Dittrich S, Emperador D, Hooft L, Spijker R, Takwoingi Y, Van den Bruel A, Wang J, Langendam M, Verbakel JY, Leeflang MM, Cochrane COVID-19 Diagnostic Test Accuracy Group
- Issue date: 2020 Nov 19
- Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study.
- Authors: Pan F, Yang L, Li Y, Liang B, Li L, Ye T, Li L, Liu D, Gui S, Hu Y, Zheng C
- Issue date: 2020
- Prognostic implications of neutrophil-lymphocyte ratio in COVID-19.
- Authors: Jimeno S, Ventura PS, Castellano JM, García-Adasme SI, Miranda M, Touza P, Lllana I, López-Escobar A
- Issue date: 2021 Jan
- Preinfection laboratory parameters may predict COVID-19 severity in tumor patients.
- Authors: Kiani A, Roesch R, Wendtner CM, Kullmann F, Kubin T, Südhoff T, Augustin M, Schaich M, Müller-Naendrup C, Illerhaus G, Hartmann F, Hebart H, Seggewiss-Bernhardt R, Bentz M, Späth-Schwalbe E, Reimer P, Kaiser U, Kapp M, Graeven U, Chemnitz JM, Baesecke J, Lambertz H, Naumann R
- Issue date: 2021 Jul